Last edition
News about "novel combination therapy "
GI Innovation, Johnson & Johnson Partner for Phase Ib Trial in Advanced Prostate Cancer
GI Innovation enters clinical supply agreement with Johnson & Johnson to evaluate GI-102 and pasritamig combination therapy in metastatic castration-resistant prostate cancer patients.
Novel Combination Therapy | 21/03/2026 | By News Bureau | 153
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members